SAB Biotherapeutics (NASDAQ:SABS) Announces Quarterly Earnings Results, Beats Expectations By $0.44 EPS

SAB Biotherapeutics (NASDAQ:SABS) announced its quarterly earnings data on Friday. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.44, Zacks reports. SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%.

SAB Biotherapeutics Stock Performance

SABS stock opened at $1.79 on Friday. The firm has a 50 day moving average of $1.49 and a two-hundred day moving average of $2.55. SAB Biotherapeutics has a 12 month low of $1.00 and a 12 month high of $5.01. The company has a market capitalization of $16.63 million, a price-to-earnings ratio of -0.48 and a beta of 0.47. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09.

Wall Street Analysts Forecast Growth

Several analysts recently commented on SABS shares. Chardan Capital decreased their price target on shares of SAB Biotherapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in a research note on Tuesday, April 1st. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $11.40.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.